GeneDx Holdings Corp vs Materials Select Sector SPDR Fund — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.58B), while Materials Select Sector SPDR Fund trades at $51.45. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | XLB | |
|---|---|---|
Market Cap | $2.58B | — |
Sector | Technology | — |
52-Week High | $167.51 | $53.67 |
52-Week Low | $34.51 | $42.23 |
Enterprise Value | $2.61B | — |
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The materials sector ETF benefits from AI infrastructure trends and strong Q2 earnings momentum across the sector. Recent news highlights potential opportunities in materials as investors rotate toward tangible assets.
The outlook for XLB appears constructive given sector tailwinds from infrastructure spending and AI buildout, though cyclical recovery may be partially priced in. Key risks include materials price volatility and geopolitical supply chain pressures. Analyst sentiment is mixed with some viewing current levels as fully valued after recent sector rebound.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →